Athira Pharma Stock Today
| ATHA Stock | USD 0.33 0.01 2.94% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Athira Pharma is trading at 0.33 as of the 18th of March 2025, a 2.94 percent decrease since the beginning of the trading day. The stock's open price was 0.34. Athira Pharma has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 18th of December 2024 and ending today, the 18th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 18th of September 2020 | Category Healthcare | Classification Health Care |
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company was incorporated in 2011 and is headquartered in Bothell, Washington. Athira Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 39.04 M outstanding shares of which 888.01 K shares are presently shorted by private and institutional investors with about 4.3 trading days to cover. More on Athira Pharma
Moving together with Athira Stock
| 0.64 | A | Agilent Technologies | PairCorr |
| 0.94 | ME | 23Andme Holding | PairCorr |
| 0.89 | VANI | Vivani Medical Earnings Call This Week | PairCorr |
Moving against Athira Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Athira Stock Highlights
| CEO President | Dr MBA | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAthira Pharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Athira Pharma's financial leverage. It provides some insight into what part of Athira Pharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Athira Pharma (ATHA) is traded on NASDAQ Exchange in USA. It is located in 18706 North Creek Parkway, Bothell, WA, United States, 98011 and employs 26 people. Athira Pharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.09 M. Athira Pharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 39.04 M outstanding shares of which 888.01 K shares are presently shorted by private and institutional investors with about 4.3 trading days to cover.
Athira Pharma currently holds about 252.4 M in cash with (97.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Athira Pharma Probability Of Bankruptcy
Ownership AllocationAthira Pharma holds a total of 39.04 Million outstanding shares. Over half of Athira Pharma's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Athira Ownership Details
Athira Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-12-31 | 320.8 K | |
| Gsa Capital Partners Llp | 2024-12-31 | 296.6 K | |
| Two Sigma Advisers, Llc | 2024-12-31 | 253.3 K | |
| Renaissance Technologies Corp | 2024-12-31 | 207.3 K | |
| Royal Bank Of Canada | 2024-12-31 | 183 K | |
| Laird Norton Tyee Trust Co | 2024-12-31 | 127.3 K | |
| State Street Corp | 2024-12-31 | 107.4 K | |
| Ubs Group Ag | 2024-12-31 | 87 K | |
| Advisor Group Holdings, Inc. | 2024-12-31 | 81.3 K | |
| Perceptive Advisors Llc | 2024-12-31 | 5.4 M | |
| Bml Capital Management Llc | 2024-12-31 | 2.8 M |
Athira Pharma Historical Income Statement
Athira Stock Against Markets
Athira Pharma Corporate Management
| Mark JD | General Secretary | Profile | |
| Samantha Willing | Executive People | Profile | |
| Robert Renninger | Director Reporting | Profile | |
| Kevin Church | Chief Officer | Profile | |
| Javier MD | Chief Officer | Profile | |
| MBA MBA | CEO Pres | Profile |
Already Invested in Athira Pharma?
The danger of trading Athira Pharma is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Athira Pharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Athira Pharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Athira Pharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Athira Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Athira Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Athira Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Athira Pharma Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Athira Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Athira Pharma. If investors know Athira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Athira Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Athira Pharma is measured differently than its book value, which is the value of Athira that is recorded on the company's balance sheet. Investors also form their own opinion of Athira Pharma's value that differs from its market value or its book value, called intrinsic value, which is Athira Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Athira Pharma's market value can be influenced by many factors that don't directly affect Athira Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Athira Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Athira Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Athira Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.